BMJ Open (Sep 2021)

Protocol for implementation of the ‘AusPROM’ recommendations for elective surgery patients: a mixed-methods cohort study

  • Paul S Myles,
  • Meg E Morris,
  • Victoria Atkinson,
  • Natasha Brusco,
  • Jeffrey Woods,
  • Anita Hodge,
  • Cathy Jones,
  • Damien Lloyd,
  • Vincent Rovtar,
  • Amanda Clifford

DOI
https://doi.org/10.1136/bmjopen-2021-049937
Journal volume & issue
Vol. 11, no. 9

Abstract

Read online

Introduction Incorporating patient-reported outcome measures (PROMs) into usual care in hospitals can improve safety and quality. Gaps exist in electronic PROM (ePROM) implementation recommendations, including for elective surgery. The aims are to: (1) understand barriers and enablers to ePROM implementation in hospitals and develop Australian ePROM implementation recommendations (AusPROM); (2) test the feasibility and acceptability of the Quality of Recovery 15 item short-form (QoR-15) PROM for elective surgery patients applying the AusPROM and (3) establish if the QoR-15 PROM has concurrent validity with the EQ-5D-5L.Methods and analysis Phase I will identify staff barriers and facilitators for the implementation of the AusPROM recommendations using a Delphi technique. Phase II will determine QoR-15 acceptability for elective surgery patients across four pilot hospitals, using the AusPROM recommendations. For phase II, in addition to a consumer focus group, patients will complete brief acceptability surveys, incorporating the QoR-15, in the week prior to surgery, in the week following surgery and 4 weeks postsurgery. The primary endpoint will be 4 weeks postsurgery. Phase III will be the national implementation of the AusPROM (29 hospitals) and the concurrent validity of the QoR-15 and generic EQ-5D-5L. This protocol adopts the Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trials Protocols guidelines.Ethics and dissemination The results will be disseminated via public forums, conferences and peer-reviewed journals. Ethics approval: La Trobe University (HEC20479).Trial registration number ACTRN12621000298819 (Phase I and II) and ACTRN12621000969864 (Phase III)